Turnover: 1.598 billion EUR (2022)
Country: France
Roche Diabetes Care, a subsidiary of the Roche Group, has been working for over 40 years with its Accu-Chek brand to enable people with diabetes to lead healthy, normal lives.
The Accu-Chek portfolio offers people with diabetes and healthcare professionals innovative products and high-performance solutions for convenient, efficient and effective diabetes management, from blood glucose monitoring to information management and insulin administration.
The Accu-Chek brand encompasses blood glucose meters, insulin delivery systems, lancing devices, data management systems and training programs, helping to improve medical outcomes.
Financial Data
DUNS: 800418493
Legal Name: ROCHE
Address: 4 CRS DE L'ILE SEGUIN , 92100 BOULOGNE-BILLANCOURT
Number of employees: Entre 500 et 999 salariés (2018)
Capital: 38 168 896 EUR
Financial Data:
| Year | Turnover (€) | Net Profit (€) | Fiscal Year End | Fiscal Year Duration |
|---|---|---|---|---|
| 2019 | 999 958 361 EUR | 21 399 895 EUR | 31/12/2019 | 12 |
| 2018 | 1 059 478 865 EUR | 34 455 213 EUR | 31/12/2018 | 12 |
| 2017 | 1 307 090 113 EUR | 21 428 146 EUR | 31/12/2017 | 12 |
| 2016 | 1 414 713 077 EUR | 25 974 686 EUR | 31/12/2016 | 12 |
| 2015 | 1 417 672 964 EUR | 27 103 868 EUR | 31/12/2015 | 12 |
Studies mentioning this company
The Insulin Pump Market - France
Other companies mentioned:
- Medtronic
- Cellnovo
- Roche Diabetes Care (Roche Groupe)
- Insulet
- Ypsomed Group
- ISIS diabète (Isis Médical)
- Physidia
- Nova Medical Center
- Medtrum
- Apex Wellell
- Open APS
- Eli Lilly
- TreeFrog Therapeutics
- Boydsense